fda compounding semaglutide warning letters november 2025 Letter to Fox Corporation regarding misleading Hims & Hers Super Bowl ad – Partnership for Safe Medicines

Novo Nordisk calls out dangers of compounded GLP-1s in new ad

21.23

★★★★☆4.8 (126)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

26.65

★★★★★4.9 (98)

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

20.43

★★★★★5.0 (157)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

28.77

★★★★★4.7 (84)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

23.38

★★★★★4.9 (203)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

27.72

★★★★★5.0 (176)

September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA – Partnership for Safe Medicines

28.95

★★★★★4.8 (132)